These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15899624)

  • 1. [Cardiac dysfunction induced by trastuzumab].
    Campone M; Bourbouloux E; Fumoleau P
    Bull Cancer; 2004 Nov; 91 Suppl 3():166-73. PubMed ID: 15899624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
    Castrellon AB; Glück S
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.
    Bengala C; Zamagni C; Pedrazzoli P; Matteucci P; Ballestrero A; Da Prada G; Martino M; Rosti G; Danova M; Bregni M; Jovic G; Guarneri V; Maur M; Conte PF;
    Br J Cancer; 2006 Apr; 94(7):1016-20. PubMed ID: 16570045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations.
    Martín M; Esteva FJ; Alba E; Khandheria B; Pérez-Isla L; García-Sáenz JA; Márquez A; Sengupta P; Zamorano J
    Oncologist; 2009 Jan; 14(1):1-11. PubMed ID: 19147689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients.
    Perik PJ; de Korte MA; van Veldhuisen DJ; Gietema JA; Sleijfer DT; de Vries EG
    Expert Rev Anticancer Ther; 2007 Dec; 7(12):1763-71. PubMed ID: 18062750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
    Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
    J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.
    de Korte MA; de Vries EG; Lub-de Hooge MN; Jager PL; Gietema JA; van der Graaf WT; Sluiter WJ; van Veldhuisen DJ; Suter TM; Sleijfer DT; Perik PJ
    Eur J Cancer; 2007 Sep; 43(14):2046-51. PubMed ID: 17719768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?
    Morris PG; Hudis CA
    J Clin Oncol; 2010 Jul; 28(21):3407-10. PubMed ID: 20530269
    [No Abstract]   [Full Text] [Related]  

  • 10. Trastuzumab cardio-oncology: lessons learned.
    Frankel C
    Clin J Oncol Nurs; 2010 Oct; 14(5):630-40. PubMed ID: 20880820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab-associated cardiotoxicity.
    Keefe DL
    Cancer; 2002 Oct; 95(7):1592-600. PubMed ID: 12237930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Trastuzumab (Herceptin)].
    Tokuda Y; Suzuki Y; Saitou Y; Ohta M; Tajima T
    Gan To Kagaku Ryoho; 2002 Apr; 29(4):645-52. PubMed ID: 11977556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab-induced cardiomyopathy.
    Guglin M; Cutro R; Mishkin JD
    J Card Fail; 2008 Jun; 14(5):437-44. PubMed ID: 18514938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controversies in the use of adjuvant trastuzumab (Herceptin).
    Chowdhury S; Pickering L; Ellis P
    J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer.
    Suter TM; Cook-Bruns N; Barton C
    Breast; 2004 Jun; 13(3):173-83. PubMed ID: 15177418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical implications of trastuzumab].
    Saeki T; Takashima S
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1094-9. PubMed ID: 12938263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
    Gianni L; Salvatorelli E; Minotti G
    Cardiovasc Toxicol; 2007; 7(2):67-71. PubMed ID: 17652806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
    Guarneri V; Lenihan DJ; Valero V; Durand JB; Broglio K; Hess KR; Michaud LB; Gonzalez-Angulo AM; Hortobagyi GN; Esteva FJ
    J Clin Oncol; 2006 Sep; 24(25):4107-15. PubMed ID: 16908934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
    Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F
    Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.